Company: CDT
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024140
Chunk: 5

Company: CDT Equity Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
 of exchange rate changes on cash and cash equivalents 
     8  
     (28)
  
    Net
    change in cash 
     2,778  
     (4,009)
  
    Cash
    and cash equivalents at beginning of period 
     554  
     4,228 
  
    Cash
    and cash equivalents at end of period 
    $3,332  
    $219 

    Supplemental
    cash flow information: 

    Cash
    paid for interest 
    $-  
    $80 

    Non-cash
    investing and financing activities 

    Right-of-use
    assets obtained in exchange for operating lease liabilities 
    $-  
    $350 
  
    Issuance
    of common stock upon exercise of conversion option 
     5,950  
     - 
  
    Issuance of common stock for services 
     2,951  
     - 
  
    Purchases
    of PP&E in accounts payable 
     -  
     40 
  
    Receivables
    from issuance of warrants for lock-up 
     -  
     67 

The
accompanying notes are an integral part of these condensed consolidated financial statements.

4

CDT EQUITY INC.

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1.
Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies

CDT
Equity Inc., formerly Conduit Pharmaceuticals Inc., a Delaware corporation (“CDT” or the “Company”), is a
data-driven pharmaceutical development company focused on
identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships.
The company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and
efficient asset repositioning to accelerate the development of novel treatments.

Our
strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical
companies with strong, supporting Phase I safety data. Through advanced co-crystallization and solid-form technologies developed at our
Cambridge facilities, we improve drug properties and extend patent life by up to 20 years. In partnership with Sarborg, we also apply
AI-powered disease mapping to rapidly identify new therapeutic applications for existing compounds.

Our
pipeline includes candidates that target autoimmune disorders, as well as idi